KR101896924B1 - 신규한 항암제 - Google Patents

신규한 항암제 Download PDF

Info

Publication number
KR101896924B1
KR101896924B1 KR1020137013509A KR20137013509A KR101896924B1 KR 101896924 B1 KR101896924 B1 KR 101896924B1 KR 1020137013509 A KR1020137013509 A KR 1020137013509A KR 20137013509 A KR20137013509 A KR 20137013509A KR 101896924 B1 KR101896924 B1 KR 101896924B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
compound
independently selected
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137013509A
Other languages
English (en)
Korean (ko)
Other versions
KR20130141554A (ko
Inventor
안토니 윌크 버지스
프란체스카 워커
케이스 제프리 왓슨
헬렌 윗차드
기욤 레슨
Original Assignee
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 filed Critical 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치
Publication of KR20130141554A publication Critical patent/KR20130141554A/ko
Application granted granted Critical
Publication of KR101896924B1 publication Critical patent/KR101896924B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137013509A 2010-10-27 2011-10-27 신규한 항암제 Expired - Fee Related KR101896924B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40726510P 2010-10-27 2010-10-27
US61/407,265 2010-10-27
PCT/AU2011/001376 WO2012054978A1 (en) 2010-10-27 2011-10-27 Novel anti-cancer agents

Publications (2)

Publication Number Publication Date
KR20130141554A KR20130141554A (ko) 2013-12-26
KR101896924B1 true KR101896924B1 (ko) 2018-09-10

Family

ID=45992970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137013509A Expired - Fee Related KR101896924B1 (ko) 2010-10-27 2011-10-27 신규한 항암제

Country Status (12)

Country Link
US (3) US8835629B2 (enExample)
EP (1) EP2632916B1 (enExample)
JP (2) JP6184866B2 (enExample)
KR (1) KR101896924B1 (enExample)
CN (1) CN103476769B (enExample)
AU (1) AU2011320024B2 (enExample)
CA (1) CA2814120C (enExample)
ES (1) ES2621932T3 (enExample)
HU (1) HUE032522T2 (enExample)
NZ (1) NZ609186A (enExample)
PL (1) PL2632916T3 (enExample)
WO (1) WO2012054978A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814120C (en) * 2010-10-27 2018-08-07 The Walter And Eliza Hall Institute Of Medical Research Novel anti-cancer agents
KR101853785B1 (ko) 2013-11-20 2018-05-02 주식회사 만도 3상모터 제어장치 및 그의 고토크 유지 방법
WO2016070241A1 (en) * 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
US20200128829A1 (en) * 2017-06-08 2020-04-30 University Of South Alabama Antimicrobial Compounds
EA202091481A1 (ru) 2018-01-17 2020-12-03 Ориджен Дискавери Текнолоджис Лимитед Замещенные алкиниленовые соединения в качестве противораковых агентов

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032903A2 (en) 2001-10-12 2003-04-24 New York University Trisubstituted triazines compounds with antitubulin activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) 1956-04-17 Chx n nhx c c
GB1035771A (enExample)
US3145203A (en) 1961-11-30 1964-08-18 Geigy Chem Corp Hydrazones of 5-nitro-2-furaldehyde
JPS5277163A (en) 1975-12-24 1977-06-29 Asahi Chem Ind Co Ltd Stabilized polyurethane composition
FR2524467A1 (fr) 1982-03-30 1983-10-07 Adir Polymethylene-imines disubstituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
JPS62192474A (ja) 1986-02-19 1987-08-24 Canon Inc 記録液
US4932998A (en) 1986-09-30 1990-06-12 Idemitsu Kosan Company Limited Triazine derivatives, and herbicides comprising the same as the effective ingredient
US4844731A (en) 1986-12-27 1989-07-04 Idemitsu Company Co., Ltd. Triazine derivatives
US5187045A (en) 1988-09-07 1993-02-16 Minnesota Mining And Manufacturing Company Halomethyl-1,3,5-triazines containing a sensitizer moiety
DK0411153T3 (enExample) 1989-02-20 1997-02-10 Idemitsu Kosan Co
WO1993010116A1 (en) 1991-11-12 1993-05-27 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
FR2757056B1 (fr) 1996-12-17 2003-03-14 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un compose amide et utilisations
FR2757057A1 (fr) 1996-12-17 1998-06-19 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un derive silicie a fonction benzalmalonate et utilisations
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
US6262053B1 (en) 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
KR100850812B1 (ko) 2000-10-23 2008-08-06 스미스클라인 비참 코포레이션 신규 화합물
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CN1697831A (zh) * 2002-09-23 2005-11-16 雷迪美国治疗公司 新三嗪化合物的制备方法和组合物
CA2814120C (en) * 2010-10-27 2018-08-07 The Walter And Eliza Hall Institute Of Medical Research Novel anti-cancer agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032903A2 (en) 2001-10-12 2003-04-24 New York University Trisubstituted triazines compounds with antitubulin activity

Also Published As

Publication number Publication date
ES2621932T3 (es) 2017-07-05
US8835629B2 (en) 2014-09-16
KR20130141554A (ko) 2013-12-26
EP2632916A1 (en) 2013-09-04
JP2013540778A (ja) 2013-11-07
CA2814120A1 (en) 2012-05-03
EP2632916B1 (en) 2017-01-11
WO2012054978A1 (en) 2012-05-03
JP6184866B2 (ja) 2017-08-23
EP2632916A4 (en) 2014-04-23
JP2017137323A (ja) 2017-08-10
CN103476769A (zh) 2013-12-25
US20160145243A1 (en) 2016-05-26
CN103476769B (zh) 2016-06-01
HUE032522T2 (en) 2017-09-28
US9221799B2 (en) 2015-12-29
PL2632916T3 (pl) 2017-07-31
NZ609186A (en) 2015-08-28
CA2814120C (en) 2018-08-07
AU2011320024B2 (en) 2014-10-30
AU2011320024A1 (en) 2013-05-02
US20130261119A1 (en) 2013-10-03
US20150045365A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
ES2620316T3 (es) Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
ES2906785T3 (es) Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones
CN114555586A (zh) 新颖的krasg12c蛋白抑制剂及其制备方法和用途
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
JP2018024713A (ja) 上皮成長因子受容体キナーゼ阻害剤の固体形態
KR101896924B1 (ko) 신규한 항암제
KR20220108070A (ko) 신규 오로라 키나아제 억제제 및 이의 용도
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
KR20090116716A (ko) 칸나비노이드-ｃｂ1 길항작용과 아세틸콜린에스테라제 억제가 조합된 화합물
EP3845538A1 (en) Dihydroimidazopyrazinone compound, composition including same, and use thereof
EP4431098A1 (en) Pharmaceutical composition for providing treatment for or preventing alport syndrome
KR101872264B1 (ko) 신규한 유형의 시티딘 유도체 이량체 및 그의 용도
CN119490500A (zh) 一种prmt5抑制剂、其制备方法及应用
CN118684666A (zh) Kif18a抑制剂及其用途
AU2016304331A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
JP2008545803A5 (enExample)
ES2559295T3 (es) Un compuesto para el tratamiento de la hepatitis C
CN114616229B (zh) 三环化合物及其药物用途
AU2014280992A1 (en) Novel Anti-Cancer Agents
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK1257988B (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-5-5-R10-R15-oth-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-5-5-R10-R16-oth-X000

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20181017

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1018969240000

Gazette reference publication date: 20180910

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240905

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240905